Skip to main content

Table 4 Geometric mean concentrations (GMC) of measles, mumps, rubella and varicella antibodies at 42 days post-vaccination for children initially seronegative to measles, mumps, rubella or varicella in the antigen-specific per-protocol sets

From: Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial

 

IM Group

N= 3741

SC Group

N= 3781

 

n 2

GMC

[95% CI]

n 2

GMC

[95% CI]

Measles (mIU/ml)

349

2396.4

[2117.7; 2711.8]

363

2560.6

[2278.5; 2877.7]

Mumps (ELISA Ab units/ml)

349

86.4

[78.7; 95.0]

363

89.8

[82.6; 97.6]

Rubella (IU/ml)

321

97.2

[88.6; 106.7]

318

94.4

[85.7; 104.0]

Varicella (gpELISA units/ml)

333

9.8

[9.2; 10.5]

345

9.2

[8.6; 9.8]

  1. (IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route; ELISA, enzyme-linked immunosorbent assay; Ab, antibody, gpELISA, glycoprotein antigen-based enzyme-linked immunosorbent assay.)
  2. 1Number of vaccinated subjects
  3. 2Number of subjects initially seronegative to measles, mumps, rubella or varicella contributing to each per-protocol set
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us